RU2009115363A - Антагонисты рецепторов для лечения метастатического рака - Google Patents
Антагонисты рецепторов для лечения метастатического рака Download PDFInfo
- Publication number
- RU2009115363A RU2009115363A RU2009115363/15A RU2009115363A RU2009115363A RU 2009115363 A RU2009115363 A RU 2009115363A RU 2009115363/15 A RU2009115363/15 A RU 2009115363/15A RU 2009115363 A RU2009115363 A RU 2009115363A RU 2009115363 A RU2009115363 A RU 2009115363A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- antibody
- tumor
- antibody fragment
- pdgfrα
- Prior art date
Links
- 208000037819 metastatic cancer Diseases 0.000 title 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract 28
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract 28
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims abstract 16
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims abstract 16
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 6
- 239000012634 fragment Substances 0.000 claims abstract 6
- 108091033319 polynucleotide Proteins 0.000 claims abstract 5
- 239000002157 polynucleotide Substances 0.000 claims abstract 5
- 102000040430 polynucleotide Human genes 0.000 claims abstract 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- 229940127121 immunoconjugate Drugs 0.000 claims abstract 2
- 239000003446 ligand Substances 0.000 claims abstract 2
- 230000008685 targeting Effects 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940123011 Growth factor receptor antagonist Drugs 0.000 claims 1
- 229940124043 Insulin-like growth factor receptor antagonist Drugs 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Выделенное антитело или фрагмент антитела человека, специфическое в отношении PDGFRα, включающее один или несколько гипервариабельных участков, выбранных из группы, состоящей из SEQ ID NO:2 при CDRH1; SEQ ID NO:4 при CDRH2; SEQ ID NO:6 при CDRH3; SEQ ID NO:10 при CDRL1; SEQ ID NO:12 при CDRL2; и SEQ ID NO:14 при CDRL3. ! 2. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:2 при CDRH1; SEQ ID NO:4 при CDRH2; SEQ ID NO:6 при CDRH3. ! 3. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:8. !4. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:10 при CDRL1; SEQ ID NO:12 при CDRL2; и SEQ ID NO:14 при CDRL3. ! 5. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:16. ! 6. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:2 при CDRH1; SEQ ID NO:4 при CDRH2; SEQ ID NO:6 при CDRH3; SEQ ID NO:10 при CDRL1; SEQ ID NO:12 при CDRL2; и SEQ ID NO:14 при CDRL3. ! 7. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:8 и SEQ ID NO:16. ! 8. Антитело или фрагмент антитела по любому из пп.1-7, которое селективно связывается с PDGFRα. ! 9. Антитело или фрагмент антитела по любому из пп.1-7, которое ингибирует связывание PDGFRα с лигандом PDGFRα. ! 10. Антитело или фрагмент антитела по любому из пп.1-7, которое нейтрализует PDGFRα. ! 11. Антитело или фрагмент антитела по любому из пп.1-7, где фрагмент антитела выбран из группы, состоящей из одноцепочечного антитела, Fab, одноцепочечного Fv, диатела и триатела. ! 12. Конъюгат антитела или фрагмента антитела по любому из пп.1-7. ! 13. Конъюгат антитела по п.12, который включает противоопухолевое средство, целенаправляющий фрагмент и репортерный фрагмент. ! 14. Выделенный полинуклеотид, который кодирует антитело или фрагмент антитела и включает одну или несколько последовательностей нуклеотидов, выбранную из группы, включ�
Claims (37)
1. Выделенное антитело или фрагмент антитела человека, специфическое в отношении PDGFRα, включающее один или несколько гипервариабельных участков, выбранных из группы, состоящей из SEQ ID NO:2 при CDRH1; SEQ ID NO:4 при CDRH2; SEQ ID NO:6 при CDRH3; SEQ ID NO:10 при CDRL1; SEQ ID NO:12 при CDRL2; и SEQ ID NO:14 при CDRL3.
2. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:2 при CDRH1; SEQ ID NO:4 при CDRH2; SEQ ID NO:6 при CDRH3.
3. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:8.
4. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:10 при CDRL1; SEQ ID NO:12 при CDRL2; и SEQ ID NO:14 при CDRL3.
5. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:16.
6. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:2 при CDRH1; SEQ ID NO:4 при CDRH2; SEQ ID NO:6 при CDRH3; SEQ ID NO:10 при CDRL1; SEQ ID NO:12 при CDRL2; и SEQ ID NO:14 при CDRL3.
7. Антитело или фрагмент антитела по п.1, которое включает SEQ ID NO:8 и SEQ ID NO:16.
8. Антитело или фрагмент антитела по любому из пп.1-7, которое селективно связывается с PDGFRα.
9. Антитело или фрагмент антитела по любому из пп.1-7, которое ингибирует связывание PDGFRα с лигандом PDGFRα.
10. Антитело или фрагмент антитела по любому из пп.1-7, которое нейтрализует PDGFRα.
11. Антитело или фрагмент антитела по любому из пп.1-7, где фрагмент антитела выбран из группы, состоящей из одноцепочечного антитела, Fab, одноцепочечного Fv, диатела и триатела.
12. Конъюгат антитела или фрагмента антитела по любому из пп.1-7.
13. Конъюгат антитела по п.12, который включает противоопухолевое средство, целенаправляющий фрагмент и репортерный фрагмент.
14. Выделенный полинуклеотид, который кодирует антитело или фрагмент антитела и включает одну или несколько последовательностей нуклеотидов, выбранную из группы, включающей SEQ ID NO:1 при CDRH1; SEQ ID NO:3 при CDRH2; SEQ ID NO:5 при CDRH3; SEQ ID NO:9 при CDRL1; SEQ ID NO:11 при CDRL2; и SEQ ID NO:13 при CDRL3.
15. Выделенный полинуклеотид по п.14, который включает SEQ ID NO:7.
16. Выделенный полинуклеотид по п.14, который включает SEQ ID NO:15.
17. Вектор экспрессии, включающий полинуклеотид по любому из пп.14-16.
18. Рекомбинантная клетка-хозяин, включающая вектор экспрессии по п.17.
19. Рекомбинантная клетка-хозяин по п.18, продуцирующая полипептид, включающий SEQ ID NO:8 и полипептид, включающий SEQ ID NO:16.
20. Рекомбинантная клетка-хозяин по п.18, продуцирующая полипептид, включающий SEQ ID NO:8 и SEQ ID NO:16.
21. Способ нейтрализации активации PDGFRα у млекопитающего, включающий введение эффективного количества антитела по любому из пп.1-11.
22. Способ ингибирования роста опухоли у млекопитающего, включающий введение терапевтически эффективного количества антитела по любому из пп.1-11.
23. Способ по п.22, где опухоль экспрессирует PDGFRα.
24. Способ по п.22, где опухоль сверхэкспрессирует PDGFRα.
25. Способ по п.22, где опухоль представляет собой первичную опухоль.
26. Способ по п.22. где опухоль представляет собой метастатическую опухоль.
27. Способ по п.22, где опухоль представляет собой не поддающуюся лечению опухоль.
28. Способ по п.22, где опухоль представляет собой васкуляризированную опухоль.
29. Способ по п.22, где опухоль выбирают из группы, состоящей из опухоли яичника, опухоли молочной железы, опухоли легкого, гепатоклеточной опухоли, опухоли стромальных клеток желудочно-кишечного тракта, меланомы, почечно-клеточной карциномы, опухоли предстательной железы и саркомы мягких тканей.
30. Способ по п.22, где антитело или фрагмент антитела применяют в сочетании с противоопухолевым средством.
31. Способ по п.30, где противоопухолевое средство представляет собой химиотерапевтический агент.
32. Способ по п.30, где противоопухолевое средство представляет собой доксорубицин.
33. Способ по п.30, где противоопухолевое средство представляет собой облучение.
34. Способ по п.22, где антитело или фрагмент антитела вводят совместно со вторым антагонистом PDGFRα.
35. Способ по п.34, где антагонист PDGFRα представляет собой внутриклеточный антагонист PDGFRα.
36. Способ по п.22, дополнительно включающий введение терапевтически эффективного количества антагониста рецептора эпителиального фактора роста (EGFR).
37. Способ по п.22, дополнительно включающий введение терапевтически эффективного количества антагониста рецептора инсулиноподобного фактора роста (IGF-IR).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69192005P | 2005-06-17 | 2005-06-17 | |
| US60/691,920 | 2005-06-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008101772/14A Division RU2008101772A (ru) | 2005-06-17 | 2006-06-19 | Антагонисты рецепторов для лечения метастатического рака |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2009115363A true RU2009115363A (ru) | 2010-10-27 |
| RU2455026C2 RU2455026C2 (ru) | 2012-07-10 |
| RU2455026C3 RU2455026C3 (ru) | 2020-04-08 |
Family
ID=37571297
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009115364/15A RU2502523C2 (ru) | 2005-06-17 | 2006-06-19 | АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ |
| RU2008101772/14A RU2008101772A (ru) | 2005-06-17 | 2006-06-19 | Антагонисты рецепторов для лечения метастатического рака |
| RU2009115363A RU2455026C3 (ru) | 2005-06-17 | 2009-04-22 | Антагонисты рецепторов для лечения метастатического рака |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009115364/15A RU2502523C2 (ru) | 2005-06-17 | 2006-06-19 | АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ |
| RU2008101772/14A RU2008101772A (ru) | 2005-06-17 | 2006-06-19 | Антагонисты рецепторов для лечения метастатического рака |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8128929B2 (ru) |
| EP (4) | EP2100614B8 (ru) |
| JP (4) | JP2009501141A (ru) |
| KR (3) | KR101246504B1 (ru) |
| CN (3) | CN101612399B (ru) |
| BR (2) | BRPI0622073A8 (ru) |
| CA (3) | CA2612449A1 (ru) |
| CY (3) | CY1114603T1 (ru) |
| DK (2) | DK2100618T3 (ru) |
| ES (2) | ES2452115T3 (ru) |
| HU (1) | HUS1700015I1 (ru) |
| IL (3) | IL188151A0 (ru) |
| LT (1) | LTC2100614I2 (ru) |
| LU (1) | LUC00012I2 (ru) |
| NL (1) | NL300869I2 (ru) |
| PL (2) | PL2100614T3 (ru) |
| PT (2) | PT2100614E (ru) |
| RU (3) | RU2502523C2 (ru) |
| SI (2) | SI2100614T1 (ru) |
| WO (1) | WO2006138729A2 (ru) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2502523C2 (ru) * | 2005-06-17 | 2013-12-27 | Имклоун Элэлси | АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ |
| KR101353706B1 (ko) * | 2006-02-03 | 2014-02-18 | 유니버시티 오브 워싱톤 | 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제 |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| WO2009021150A2 (en) * | 2007-08-08 | 2009-02-12 | California Pacific Medical Center | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
| AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| US20090280112A1 (en) * | 2008-05-05 | 2009-11-12 | The Regents Of The University Of California | Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| MX344382B (es) | 2009-10-23 | 2016-12-14 | Amgen Inc * | Adaptador de vial y sistema. |
| DK2575935T4 (da) | 2010-06-07 | 2023-11-27 | Amgen Inc | Anordning til indgivelse af lægemiddel |
| JP2013177317A (ja) * | 2010-06-24 | 2013-09-09 | Meneki Seibutsu Kenkyusho:Kk | 抗ｐｄｇｆ受容体抗体 |
| US8754195B2 (en) | 2010-07-02 | 2014-06-17 | Medimmune, Llc | Antibody formulations |
| MX2013008833A (es) | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
| US9480624B2 (en) | 2011-03-31 | 2016-11-01 | Amgen Inc. | Vial adapter and system |
| EP2699293B8 (en) | 2011-04-20 | 2022-07-20 | Amgen Inc. | Autoinjector apparatus |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| EP3045188B1 (en) | 2011-10-14 | 2020-12-23 | Amgen Inc. | Injector and method of assembly |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
| EP2922590B1 (en) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Drug delivery device |
| JP6255038B2 (ja) | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス，インク． | 癌治療 |
| EP2964676A1 (en) | 2013-03-06 | 2016-01-13 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| CN111617347B (zh) | 2013-03-15 | 2023-09-29 | 安进公司 | 身体轮廓可调适的自动注射器装置 |
| EP2968760B1 (en) | 2013-03-15 | 2024-01-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| EP2968775B1 (en) | 2013-03-15 | 2019-12-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
| BR112015024282B1 (pt) | 2013-03-22 | 2022-05-17 | Amgen Inc | Injetor e método de montagem do injetor |
| CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
| EP3421066B1 (en) | 2013-10-24 | 2021-03-03 | Amgen Inc. | Injector and method of assembly |
| CN110898312B (zh) * | 2013-12-20 | 2022-11-15 | 波士顿科学国际有限公司 | 集成导管系统 |
| US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
| KR102496507B1 (ko) | 2014-05-07 | 2023-02-03 | 암겐 인코포레이티드 | 충격 감소 요소들을 가진 자동 주사기 |
| KR102710533B1 (ko) | 2014-06-03 | 2024-09-26 | 암겐 인코포레이티드 | 제어 가능한 약물 전달 시스템 및 사용 방법 |
| CN106470698A (zh) * | 2014-07-03 | 2017-03-01 | 英克隆有限责任公司 | 组合疗法 |
| MA40368A (fr) | 2014-07-03 | 2017-05-10 | Imclone Llc | Traitement de tumeurs stromales gastro-intestinales (tsgi) |
| EP3206739B1 (en) | 2014-10-14 | 2021-12-01 | Amgen Inc. | Drug injection device with visual and audio indicators |
| JP6709215B2 (ja) | 2014-10-27 | 2020-06-10 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 抗ｔｉｍ−３抗体 |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| EP3848072A1 (en) | 2014-12-19 | 2021-07-14 | Amgen Inc. | Drug delivery device with proximity sensor |
| ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
| US10583245B2 (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
| ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
| WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
| ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
| BR112018010743B1 (pt) | 2015-12-16 | 2024-02-15 | Regeneron Pharmaceuticals, Inc | Método para fabricação de um pó farmacêutico formulado, e, pó farmacêutico formulado |
| WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
| ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
| US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
| US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
| ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
| WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
| US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
| MA45493A (fr) * | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
| CA3031724C (en) * | 2016-07-28 | 2021-07-06 | Elanco Us Inc. | Anti-canine platelet derived growth factor receptor alpha antibody |
| WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
| EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
| MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
| JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
| EP3592403B1 (en) | 2017-03-06 | 2025-08-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
| CA3052482A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
| US11986624B2 (en) | 2017-03-09 | 2024-05-21 | Amgen Inc. | Insertion mechanism for drug delivery device |
| WO2018169779A1 (en) | 2017-03-17 | 2018-09-20 | ImClone, LLC | Combination therapy for pancreatic cancer |
| CN114588404B (zh) | 2017-03-28 | 2024-07-09 | 美国安进公司 | 柱塞杆和注射器组件系统以及方法 |
| AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
| US11590294B2 (en) | 2017-06-08 | 2023-02-28 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
| AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
| AU2018290302B2 (en) | 2017-06-23 | 2024-02-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
| ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
| JP7649105B2 (ja) | 2017-07-21 | 2025-03-19 | アムジエン・インコーポレーテツド | 薬物容器のためのガス透過性シーリング部材及び組立方法 |
| MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
| WO2019022951A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF |
| US12318593B2 (en) | 2017-08-09 | 2025-06-03 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
| EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
| US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
| WO2019070497A1 (en) | 2017-10-04 | 2019-04-11 | Imclone Llc | POLY THERAPY AGAINST CANCER |
| WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
| CN111132711B (zh) | 2017-10-06 | 2022-07-01 | 安进公司 | 带有联锁组件的药物递送装置及相关组装方法 |
| EP3694578B1 (en) | 2017-10-09 | 2025-09-24 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
| EP3703779A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
| MA50553A (fr) | 2017-11-06 | 2020-09-16 | Amgen Inc | Dispositif d'administration de médicament avec détection de positionnement et de débit |
| WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
| SG11202002966QA (en) | 2017-11-10 | 2020-05-28 | Amgen Inc | Plungers for drug delivery devices |
| CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
| WO2019099322A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
| WO2019231803A1 (en) | 2018-05-31 | 2019-12-05 | Imclone Llc | Combination therapy for soft tissue sarcoma |
| US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
| WO2020023451A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
| US12303677B2 (en) | 2018-07-24 | 2025-05-20 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
| WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
| MA53320A (fr) | 2018-07-31 | 2021-11-03 | Amgen Inc | Ensemble de trajet de fluide pour dispositif d'administration de médicament |
| WO2020068623A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
| IL281469B2 (en) | 2018-09-28 | 2024-08-01 | Amgen Inc | Muscle wire escapement activation assembly for a drug delivery device |
| SG11202103236YA (en) | 2018-10-02 | 2021-04-29 | Amgen Inc | Injection systems for drug delivery with internal force transmission |
| WO2020072846A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
| AU2019361919B2 (en) | 2018-10-15 | 2024-09-26 | Amgen Inc. | Drug delivery device having damping mechanism |
| EP3866889A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Platform assembly process for drug delivery device |
| IL281908B2 (en) | 2018-11-01 | 2025-06-01 | Amgen Inc | Drug delivery devices with partial drug delivery member retraction |
| TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
| US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
| EP3883610A4 (en) | 2018-11-20 | 2022-11-02 | Cornell University | MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY |
| CN109134655B (zh) * | 2018-11-28 | 2019-02-26 | 上海复宏汉霖生物技术股份有限公司 | 一种抗PDGFRα的单克隆抗体及其制备方法和应用 |
| ES3032751T3 (en) | 2019-04-24 | 2025-07-24 | Amgen Inc | Syringe sterilization verification assemblies and methods |
| MX2022002149A (es) | 2019-08-23 | 2022-03-17 | Amgen Inc | Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados. |
| JP7551744B2 (ja) | 2019-10-15 | 2024-09-17 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株 |
| CN118767143A (zh) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| CA3210922A1 (en) * | 2021-03-19 | 2022-09-22 | Gerard Joseph OAKLEY III | Methods of treating cancer with pdgfr alpha inhibitors |
| CA3217207A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
| KR20240115979A (ko) | 2021-11-08 | 2024-07-26 | 프로젠토스 테라퓨틱스, 인크. | 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도 |
| WO2024207046A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Reagents and methods for imaging cancers expressing pdgfralpha |
| WO2024207070A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Methods of treating cancers expressing pdgfralpha |
| WO2024207069A1 (en) * | 2023-04-04 | 2024-10-10 | Telix Pharmaceuticals (Innovations) Pty Ltd | Reagents and methods for imaging cancers expressing pdgfralpha |
| AU2023439766A1 (en) * | 2023-04-04 | 2025-09-11 | Eli Lilly And Company | Methods of treating cancers expressing pdgfralpha |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585344A (en) * | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4774321A (en) * | 1986-12-01 | 1988-09-27 | Massachusetts Institute Of Technology | DP100 EGF and insulin-binding protein from Drosophila cells |
| WO1988007863A1 (en) | 1987-04-06 | 1988-10-20 | Biogrowth, Inc. | Human somatomedin carrier protein subunits and process for producing them |
| US5200509A (en) * | 1987-04-06 | 1993-04-06 | Celtrix Pharmaceuticals, Inc. | Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| ATE119198T1 (de) | 1988-04-16 | 1995-03-15 | Celltech Ltd | Verfahren zur herstellung von proteinen mittels rekombinanter dna. |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| GB8826451D0 (en) | 1988-11-11 | 1988-12-14 | Sandoz Ltd | Improvements in/relating to organic compounds |
| IL92816A0 (en) | 1988-12-22 | 1990-09-17 | Biogrowth Inc | Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides |
| US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| JP2640568B2 (ja) * | 1989-02-09 | 1997-08-13 | アメリカ合衆国 | タイプα血小板由来増殖因子レセプター遺伝子 |
| US6228600B1 (en) * | 1992-07-20 | 2001-05-08 | The United States Of America As Represented By The Department Of Health And Human Services | Immunoassays for the alpha platelet-derived growth factor receptor |
| US7252929B2 (en) * | 1989-02-09 | 2007-08-07 | United States Of America, As Represented By The Secretary, Dept Of Health & Human Services | Methods for identifying alpha PDGFR agonists and antagonists |
| US5468468A (en) * | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
| AU658567B2 (en) | 1990-04-16 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Styryl-substituted indole and pyridyl compounds |
| CA2090703A1 (en) * | 1990-08-28 | 1992-03-01 | Michael C. Kiefer | Insulin-like growth factor binding protein (igfbp-4) |
| AU1411092A (en) * | 1991-01-31 | 1992-09-07 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5262308A (en) * | 1992-01-28 | 1993-11-16 | Thomas Jefferson University | Cell lines which constitutively express IGF-1 and IGF-1 R |
| AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
| US5597563A (en) * | 1992-09-04 | 1997-01-28 | Beschorner; William E. | Method induction of antigen-specific immune tolerance |
| US5869337A (en) * | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5620687A (en) * | 1993-02-25 | 1997-04-15 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors |
| ATE170402T1 (de) | 1993-02-25 | 1998-09-15 | Zymogenetics Inc | Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima |
| US5976534A (en) * | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
| EP0694069A1 (en) * | 1993-04-06 | 1996-01-31 | Cedars-Sinai Medical Center | Variant insulin-like growth factor i receptor subunits and methods for use thereof |
| AU1518595A (en) * | 1994-01-14 | 1995-08-01 | Genentech Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US5532159A (en) * | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US5597700A (en) * | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
| JPH10505819A (ja) * | 1994-06-24 | 1998-06-09 | ヴラディミール ピー． トーチリン | 腫瘍の治療及び予防のための自己抗体の使用方法 |
| US5939269A (en) * | 1994-12-28 | 1999-08-17 | The Regents Of The University Of California | Antagonists to insulin receptor tyrosine kinase inhibitor |
| ES2161290T3 (es) | 1995-03-30 | 2001-12-01 | Pfizer | Derivados de quinazolina. |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JP2000500654A (ja) * | 1995-11-14 | 2000-01-25 | トーマス・ジェファーソン・ユニバーシティ | 可溶性ｉｇｆ−１受容体による腫瘍成長に対する誘導耐性 |
| AU1441497A (en) | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| AUPN999096A0 (en) | 1996-05-22 | 1996-06-13 | Northstar Biologicals Pty Ltd | Peptides, antibodies, vaccines & uses thereof |
| DE69734513T2 (de) | 1996-06-24 | 2006-07-27 | Pfizer Inc. | Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten |
| US5798266A (en) * | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
| US6071891A (en) * | 1996-11-22 | 2000-06-06 | Regents Of The University Of Minnesota | Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition |
| AU749750B2 (en) | 1997-02-05 | 2002-07-04 | Warner-Lambert Company | Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| CZ20004224A3 (cs) | 1998-05-15 | 2002-02-13 | Imclone Systems Incorporated | Neradioaktivně značený inhibitor proteinového tyrosinkinázového receptoru |
| ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
| US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
| NZ510551A (en) | 1998-09-29 | 2003-03-28 | American Cyanamid Co | Substituted 3-cyanoquinolines useful as protein tyrosine kinases inhibitors |
| HK1039749B (zh) * | 1998-10-05 | 2007-10-05 | 法麦克萨有限公司 | Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用 |
| CA2349721A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl|-acrylamide, an irreversible inhibitor of tyrosine kinases |
| EP1006184A1 (en) * | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
| US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| AU777496B2 (en) | 1999-07-27 | 2004-10-21 | Michael Miravet Sorribes | A device for non-invasively correcting the shape of a human external ear |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| RU2183461C2 (ru) * | 2000-05-29 | 2002-06-20 | Ростовский научно-исследовательский онкологический институт МЗ РФ | Способ лечения сарком мягких тканей |
| US7329745B2 (en) * | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
| US20030165502A1 (en) * | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
| EP1295939A4 (en) * | 2000-06-15 | 2005-02-02 | Kyowa Hakko Kogyo Kk | INSULIN SIMILAR GROWTH FACTOR BINDING PROTEIN |
| US8153121B2 (en) * | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
| SG138469A1 (en) * | 2001-01-05 | 2008-01-28 | Pfizer | Antibodies to insulin-like growth factor i receptor |
| IL157705A0 (en) * | 2001-03-14 | 2004-03-28 | Genentech Inc | Igf antagonist peptides |
| US20040116330A1 (en) * | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
| US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| US7553485B2 (en) * | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
| ES2427964T3 (es) | 2002-01-18 | 2013-11-05 | Pierre Fabre Medicament | Nuevos anticuerpos anti-IGF-IR y sus aplicaciones |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| EP1916001B1 (en) | 2002-03-04 | 2011-05-25 | Imclone LLC | Human antibodies specific to KDR and uses thereof |
| WO2003100008A2 (en) * | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| CA2492092A1 (en) * | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| EP1546203B1 (en) * | 2002-08-01 | 2012-06-20 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US20040102360A1 (en) * | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| AU2004212344B2 (en) | 2003-02-13 | 2009-05-07 | Pfizer Products Inc. | Uses of anti-insulin-like growth factor I receptor antibodies |
| BRPI0408317A (pt) * | 2003-03-14 | 2006-03-07 | Pharmacia Corp | anticorpos do receptor de igf-i para o tratamento de cáncer |
| EP1613658B1 (en) | 2003-04-02 | 2012-03-14 | F. Hoffmann-La Roche AG | Antibodies against insulin-like growth factor i receptor and uses thereof |
| JP2007535895A (ja) | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−１受容体に対する完全ヒト抗体 |
| RU2241452C1 (ru) * | 2003-06-11 | 2004-12-10 | Московский областной научно-исследовательский клинический институт | Способ лечения метастазов в кости |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| US20050079184A1 (en) * | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| CN1835975B (zh) * | 2003-08-13 | 2012-11-21 | 辉瑞产品公司 | 经修饰的人类igf-1r抗体 |
| JPWO2005018671A1 (ja) | 2003-08-21 | 2006-10-19 | 協和醗酵工業株式会社 | 癌転移阻害剤 |
| EP1671647A1 (en) * | 2003-09-24 | 2006-06-21 | Kyowa Hakko Kogyo Co., Ltd. | Medicament for treating cancer |
| PE20050928A1 (es) | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
| US7781393B2 (en) | 2004-02-25 | 2010-08-24 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting tumor cell growth |
| DE602005027673D1 (de) * | 2004-03-05 | 2011-06-09 | Vegenics Pty Ltd | Materialien und verfahren für wachstumsfaktorbindende konstrukte |
| JP4493485B2 (ja) | 2004-04-28 | 2010-06-30 | シャープ株式会社 | 太陽電池モジュール用配線部材、それを用いた太陽電池モジュールおよび太陽電池モジュール用配線部材の製造方法 |
| CN101014365B (zh) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
| JP2008521907A (ja) | 2004-12-03 | 2008-06-26 | シェーリング コーポレイション | 抗ｉｇｆ１ｒ治療について患者を予め選択するためのバイオマーカー |
| US20060134172A1 (en) * | 2004-12-21 | 2006-06-22 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| AU2006236489C1 (en) * | 2005-04-15 | 2012-04-12 | Immunogen, Inc. | Elimination of heterogeneous or mixed cell population in tumors |
| RU2502523C2 (ru) * | 2005-06-17 | 2013-12-27 | Имклоун Элэлси | АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ |
| WO2007000328A1 (en) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof |
| US20070009970A1 (en) * | 2005-07-08 | 2007-01-11 | Predicant Biosciences, Inc. | Biological patterns for diagnosis and treatment of cancer |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| TWI478940B (zh) | 2005-08-26 | 2015-04-01 | Roche Glycart Ag | 具有經改變細胞傳訊活性之改質抗原結合分子 |
| US7939637B2 (en) * | 2005-12-13 | 2011-05-10 | Medimmune Limited | Insulin-like growth factor antibodies and uses thereof |
| WO2010000008A1 (en) | 2008-06-30 | 2010-01-07 | Desi Raymond Richardson | Thiosemicarbazone compounds and use thereof |
| ES2461494T3 (es) | 2008-07-18 | 2014-05-20 | F. Hoffmann-La Roche Ag | Nuevas fenilimidazopirazinas |
| DK200900548A (en) | 2008-07-18 | 2010-01-19 | Univ Koebenhavn | Processes for manufacture of products from plants |
-
2006
- 2006-06-19 RU RU2009115364/15A patent/RU2502523C2/ru not_active IP Right Cessation
- 2006-06-19 CA CA002612449A patent/CA2612449A1/en not_active Abandoned
- 2006-06-19 PT PT90751033T patent/PT2100614E/pt unknown
- 2006-06-19 CA CA2680945A patent/CA2680945C/en active Active
- 2006-06-19 CN CN2009101264326A patent/CN101612399B/zh not_active Expired - Fee Related
- 2006-06-19 DK DK09075102.5T patent/DK2100618T3/en active
- 2006-06-19 ES ES09075102.5T patent/ES2452115T3/es active Active
- 2006-06-19 EP EP09075103.3A patent/EP2100614B8/en active Active
- 2006-06-19 BR BRPI0622073A patent/BRPI0622073A8/pt not_active Application Discontinuation
- 2006-06-19 KR KR1020097003171A patent/KR101246504B1/ko active Active
- 2006-06-19 CN CNA2006800284670A patent/CN101500597A/zh active Pending
- 2006-06-19 CN CN200910126431.1A patent/CN101613409B/zh active Active
- 2006-06-19 EP EP06785127A patent/EP1909819A4/en not_active Withdrawn
- 2006-06-19 PT PT90751025T patent/PT2100618E/pt unknown
- 2006-06-19 SI SI200631722T patent/SI2100614T1/sl unknown
- 2006-06-19 EP EP09075102.5A patent/EP2100618B1/en not_active Not-in-force
- 2006-06-19 WO PCT/US2006/023856 patent/WO2006138729A2/en not_active Ceased
- 2006-06-19 KR KR1020087001415A patent/KR20080047529A/ko not_active Withdrawn
- 2006-06-19 BR BRPI0611984-0A patent/BRPI0611984A2/pt not_active IP Right Cessation
- 2006-06-19 ES ES09075103T patent/ES2435727T3/es active Active
- 2006-06-19 SI SI200631744T patent/SI2100618T1/sl unknown
- 2006-06-19 JP JP2008517219A patent/JP2009501141A/ja active Pending
- 2006-06-19 RU RU2008101772/14A patent/RU2008101772A/ru not_active Application Discontinuation
- 2006-06-19 EP EP12162951A patent/EP2505205A1/en not_active Withdrawn
- 2006-06-19 PL PL09075103T patent/PL2100614T3/pl unknown
- 2006-06-19 PL PL09075102T patent/PL2100618T3/pl unknown
- 2006-06-19 US US11/917,890 patent/US8128929B2/en active Active
- 2006-06-19 KR KR1020097003170A patent/KR101246428B1/ko not_active Expired - Fee Related
- 2006-06-19 CA CA2678008A patent/CA2678008C/en not_active Expired - Fee Related
- 2006-06-19 DK DK09075103.3T patent/DK2100614T3/da active
-
2007
- 2007-12-16 IL IL188151A patent/IL188151A0/en unknown
-
2009
- 2009-02-17 JP JP2009033517A patent/JP5436883B2/ja active Active
- 2009-02-17 JP JP2009033512A patent/JP5154470B2/ja not_active Expired - Fee Related
- 2009-04-22 RU RU2009115363A patent/RU2455026C3/ru active Protection Beyond IP Right Term
- 2009-05-21 IL IL198870A patent/IL198870A/en active Protection Beyond IP Right Term
- 2009-05-21 IL IL198869A patent/IL198869A/en not_active IP Right Cessation
-
2011
- 2011-10-19 US US13/276,358 patent/US8425911B2/en not_active Expired - Fee Related
- 2011-10-19 US US13/276,353 patent/US8574578B2/en active Active
-
2012
- 2012-06-13 JP JP2012134040A patent/JP2012179060A/ja active Pending
-
2013
- 2013-11-14 CY CY20131101013T patent/CY1114603T1/el unknown
-
2014
- 2014-04-04 CY CY20141100261T patent/CY1115076T1/el unknown
-
2017
- 2017-04-05 LU LU00012C patent/LUC00012I2/fr unknown
- 2017-04-05 CY CY2017013C patent/CY2017013I1/el unknown
- 2017-04-14 NL NL300869C patent/NL300869I2/nl unknown
- 2017-04-18 HU HUS1700015C patent/HUS1700015I1/hu unknown
- 2017-04-18 LT LTPA2017011C patent/LTC2100614I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| RU2013136172A (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP2008500815A5 (ru) | ||
| RU2006137060A (ru) | Человеческие антитела к рецептору эпидермального фактора роста | |
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| JP2012500814A5 (ru) | ||
| JP2014530017A5 (ru) | ||
| JP2019535250A5 (ru) | ||
| JP2020522486A5 (ru) | ||
| JP2013510868A5 (ru) | ||
| JP2017519759A5 (ru) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2017149720A5 (ru) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| RU2019118257A (ru) | Анти-cd47 антитела и способы их применения | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP2013529183A5 (ru) | ||
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| JP2010535713A5 (ru) | ||
| JP2013517487A5 (ru) | ||
| WO2013044215A4 (en) | Vegf/dll4 binding agents and uses thereof | |
| JP2015506912A5 (ru) | ||
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| JP2008508858A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Effective date: 20200408 |